NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.85 -0.19 (-1.58 %)
(As of 03/25/2019 04:00 PM ET)
Previous Close$12.04
Today's Range$11.72 - $12.1350
52-Week Range$10.21 - $23.64
Volume158,412 shs
Average Volume331,382 shs
Market Capitalization$653.14 million
P/E Ratio-4.17
Dividend YieldN/A
Beta1.41
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITCI
CUSIPN/A
Phone646-440-9333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$5.81 per share

Profitability

Net Income$-155,130,000.00

Miscellaneous

Employees73
Market Cap$653.14 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) posted its quarterly earnings data on Wednesday, February, 27th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.91) by $0.16. View Intra-Cellular Therapies' Earnings History.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Intra-Cellular Therapies.

What price target have analysts set for ITCI?

4 analysts have issued twelve-month price targets for Intra-Cellular Therapies' stock. Their forecasts range from $27.00 to $37.00. On average, they expect Intra-Cellular Therapies' stock price to reach $31.75 in the next year. This suggests a possible upside of 167.9% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

What is the consensus analysts' recommendation for Intra-Cellular Therapies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

What are Wall Street analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
  • 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (1/10/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and price target of $32. On Wednesday, BMO Intra-Cellular reported 3Q18 financial performance ending the period with cash of $376M. Our model projects sufficient funding through several clinical milestones including NDA acceptance/approval of lumateperone for schizophrenia and P3 data in bipolar depression (two trials, now expected in 1H19). The key questions on the earnings call, which we view as resulting in a market inefficiency, centered on the data analysis and release of the P3 401 & 404 studies of luma’ in BpD. First, we don’t expect the efficacy data for the two studies to be pooled; but analyzed separately at the same time." (11/7/2018)

Has Intra-Cellular Therapies been receiving favorable news coverage?

Headlines about ITCI stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Intra-Cellular Therapies' key competitors?

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Celgene (CELG), Synergy Pharmaceuticals (SGYP), Incyte (INCY), Gilead Sciences (GILD), Flexion Therapeutics (FLXN), Portola Pharmaceuticals (PTLA), Intercept Pharmaceuticals (ICPT), Melinta Therapeutics (MLNT), SCYNEXIS (SCYX) and Sarepta Therapeutics (SRPT).

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the folowing people:
  • Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Lawrence J. Hineline CPA, Sr. VP of Fin. & CFO (Age 63)
  • Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)
  • Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64)

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (7.32%), Dimensional Fund Advisors LP (2.64%), Dimensional Fund Advisors LP (2.64%), Samlyn Capital LLC (2.31%) and Rhenman & Partners Asset Management AB (1.21%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Which institutional investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Weiss Multi Strategy Advisers LLC, Columbus Circle Investors, SG Americas Securities LLC, Los Angeles Capital Management & Equity Research Inc., MetLife Investment Advisors LLC, New York State Common Retirement Fund and TD Asset Management Inc.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Robert E Davis and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Which institutional investors are buying Intra-Cellular Therapies stock?

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Norges Bank, General American Investors Co. Inc., Two Sigma Investments LP, First Midwest Bank Trust Division, Candriam Luxembourg S.C.A., BlackRock Inc. and Tekla Capital Management LLC. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $11.85.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $653.14 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]


MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  356 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  626
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: What is the yield curve?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel